ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aldeyra Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.67−0.03 (-5.00%)
Close on Oct 19, 2026
- Market cap
- $40.12M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
60.9%
37M of 60M shares
Institutional holders
108
19 new, 37 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
3 buys · 0 sales
Net bought $522.60K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Joseph Edelman | 5,222,311 | 8.70% | 13G (passive) amendment | Sep 30, 2025 |
| Perceptive Advisors LLC | 4,185,632 | 7.00% | 13G (passive) amendment | Dec 31, 2025 |
| AQR Capital Management Holdings, LLC | 3,751,558 | 6.22% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 5,475,516 | 9.08% | $11.66M | – | 6.50% |
| Aqr Capital Management LLC | 3,751,558 | 6.22% | $7.99M | +921,683 | 0.00% |
| Kingdon Capital Management, L.L.C. | 2,652,315 | 4.40% | $5.65M | +500,000 | 0.58% |
| Vanguard Capital Management LLC | 2,361,796 | 3.92% | $5.03M | −1,946 | 0.00% |
| D. E. Shaw & Co., Inc. | 1,940,338 | 3.22% | $4.13M | +536,348 | 0.00% |
| Marshall Wace, Llp | 1,506,974 | 2.50% | $3.21M | +1,377,281 | 0.00% |
| 683 Capital Management, LLC | 1,450,000 | 2.40% | $3.09M | −50,000 | 0.15% |
| Jane Street Group, LLC | 1,375,115 | 2.28% | $2.93M | +406,224 | 0.00% |
| BlackRock, Inc. | 1,257,243 | 2.08% | $2.68M | −2,506,644 | 0.00% |
| Qube Research & Technologies Ltd | 1,128,803 | 1.87% | $2.40M | +1,041,725 | 0.00% |
| Acadian Asset Management LLC | 1,063,793 | 1.76% | $2.26K | +205,505 | 0.00% |
| Ardsley Advisory Partners LP | 975,000 | 1.62% | $2.08M | +25,000 | 0.22% |
| Renaissance Technologies LLC | 882,000 | 1.46% | $1.88M | +18,813 | 0.00% |
| Vanguard Portfolio Management LLC | 794,863 | 1.32% | $1.69M | −12,915 | 0.00% |
| Goldman Sachs Group Inc | 725,444 | 1.20% | $1.55M | +182,298 | 0.00% |
| Jacobs Levy Equity Management, Inc | 646,840 | 1.07% | $1.38M | −149,976 | 0.00% |
| Morgan Stanley | 608,321 | 1.01% | $1.30M | +89,679 | 0.00% |
| Geode Capital Management, LLC | 596,029 | 0.99% | $1.27M | −655,623 | 0.00% |
| Dimensional Fund Advisors LP | 529,083 | 0.88% | $1.13M | −95,087 | 0.00% |
| Gsa Capital Partners Llp | 472,564 | 0.78% | $1.01K | +225,370 | 0.06% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 108 | 37M | 60.9% | 19 / 31 | 44 / 37 | 8M | 9M |
| Q1 2026 | 128 | 37M | 61.9% | 24 / 50 | 37 / 29 | 11M | 9M |
| Q4 2025 | 136 | 39M | 64.6% | 20 / 38 | 54 / 11 | 3M | 4M |
| Q3 2025 | 131 | 39M | 64.9% | 24 / 57 | 25 / 15 | 7M | 2M |
| Q2 2025 | 122 | 34M | 56.8% | 20 / 46 | 33 / 24 | 6M | 9M |
| Q1 2025 | 126 | 38M | 62.8% | 24 / 27 | 46 / 14 | 4M | 3M |
| Q4 2024 | 119 | 37M | 61.8% | 25 / 38 | 25 / 16 | 4M | 3M |
| Q3 2024 | 112 | 37M | 60.9% | 19 / 40 | 24 / 8 | 7M | 2M |
| Q2 2024 | 103 | 35M | 58.6% | 18 / 34 | 32 / 16 | 3M | 4M |
| Q1 2024 | 101 | 36M | 59.9% | 14 / 32 | 32 / 18 | 2M | 2M |
| Q4 2023 | 105 | 36M | 59.0% | 21 / 25 | 46 / 36 | 7M | 9M |
| Q3 2023 | 120 | 38M | 62.6% | 15 / 41 | 37 / 14 | 2M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ALDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,784,433 | 2.96% | $3.80M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 521,515 | 0.86% | $1.11M | 0.00% | Jun 30, 2026 |
| Vanguard Explorer Fund | 331,506 | 0.55% | $510.52K | 0.00% | Jul 31, 2026 |
| Small Company Growth Portfolio | 308,146 | 0.51% | $656.35K | 0.04% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 276,801 | 0.46% | $484.40K | 0.00% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 262,161 | 0.43% | $458.78K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 187,530 | 0.31% | $399.44K | 0.03% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 154,611 | 0.26% | $270.57K | 0.00% | May 31, 2026 |
| U.S. Micro Cap Portfolio | 140,334 | 0.23% | $216.11K | 0.00% | Jul 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 105,149 | 0.17% | $161.93K | 0.01% | Jul 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 93,498 | 0.15% | $199.15K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 85,509 | 0.14% | $149.64K | 0.00% | May 31, 2026 |
| Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF | 74,423 | 0.12% | $130.24K | 0.01% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 72,731 | 0.12% | $127.28K | 0.00% | May 31, 2026 |
| PACE Small/Medium Co Growth Equity Investments | 52,300 | 0.09% | $80.54K | 0.03% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Todd C. Brady | President and CEO, Director | 1,721,298 | 2.85% | Jun 5, 2026 |
| Michael Alfieri | Principal Financial Officer | 7,500 | 0.01% | Mar 19, 2026 |
| Stephen Machatha | Chief Development Officer | 222,010 | 0.37% | Aug 13, 2025 |
| Richard Douglas | Director | 195,000 | 0.32% | Jun 11, 2026 |
| Neal Walker | Director | 15,854 | 0.03% | Jun 11, 2026 |
| Gary M. Phillips | Director | 14,812 | 0.02% | Jun 11, 2026 |
| William D. Clark | Director | – | – | Jun 11, 2026 |
| Ben Bronstein | Director | 28,248 | 0.05% | Jun 11, 2026 |
| Darlene M. Deptula-Hicks | Director | – | – | Jun 11, 2026 |
| Nancy Miller-Rich | Director | 922 | 0.00% | Jun 11, 2026 |
| Martin Joseph Joyce | Director | 23,967 | 0.04% | Jun 12, 2025 |
| Advisors Llc Perceptive | 10% owner | 11,350,085 | 18.81% | Apr 7, 2025 |
| Life Sciences Master Fund Ltd Perceptive | 10% owner | 5,875,851 | 9.74% | Apr 7, 2025 |
| Joseph Edelman | 10% owner | 9,275,851 | 15.38% | Apr 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Todd C. Brady President and CEO, Director | Jun 3, 2026 | Buy | +250,000 | $1.67 | $417.50K | 1,721,298 |
| Richard Douglas Director | Mar 19, 2026 | Buy | +70,000 | $1.40 | $98.00K | 195,000 |
| Michael Alfieri Principal Financial Officer | Mar 18, 2026 | Buy | +5,000 | $1.42 | $7.10K | 7,500 |
| Michael Alfieri Principal Financial Officer | Aug 13, 2025 | Buy | +2,500 | $5.30 | $13.25K | 2,500 |
| Stephen Machatha Chief Development Officer | Aug 11, 2025 | Sale | −22,073 | $5.15 | $113.68K | 221,799 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Apr 3, 2025 | Sale | −3,400,000 | $1.42 | $4.83M | 5,875,851 |
| Stephen Machatha Chief Development Officer | Aug 12, 2024 | Sale | −16,041 | $4.74 | $76.03K | 236,771 |
| Bruce Greenberg See Remarks | Aug 12, 2024 | Sale | −10,834 | $4.74 | $51.35K | 126,382 |
| Joseph Edelman 10% owner | Apr 5, 2024 | Buy | +37,712 | $4.74 | $178.75K | 9,275,851 |
| Joseph Edelman 10% owner | Apr 4, 2024 | Buy | +140,281 | $4.67 | $655.11K | 9,238,139 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Apr 3, 2024 | Buy | +309,847 | $4.09 | $1.27M | 9,097,858 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Apr 2, 2024 | Buy | +186,051 | $3.44 | $640.02K | 8,788,011 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Apr 1, 2024 | Buy | +8,374 | $3.25 | $27.22K | 8,601,960 |
| Stephen Machatha Chief Development Officer | Mar 12, 2024 | Sale | −11,537 | $3.16 | $36.46K | 252,812 |
| Stephen Machatha Chief Development Officer | Mar 12, 2024 | Sale | −11,537 | $3.16 | $36.46K | 243,495 |
| Todd C. Brady President and CEO, Director | Mar 12, 2024 | Sale | −85,324 | $3.05 | $260.24K | 1,471,298 |
| Bruce Greenberg See Remarks | Mar 11, 2024 | Sale | −13,201 | $3.41 | $45.02K | 130,154 |
| Bruce Greenberg See Remarks | Mar 11, 2024 | Sale | −13,201 | $3.41 | $45.02K | 120,699 |
| Stephen Machatha Chief Development Officer | Mar 11, 2024 | Sale | −18,231 | $3.41 | $62.17K | 255,032 |
| Todd C. Brady President and CEO, Director | Mar 11, 2024 | Sale | −97,914 | $3.27 | $320.18K | 1,556,622 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Oct 18, 2023 | Sale | −306,499 | $1.74 | $533.31K | 8,593,586 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Oct 16, 2023 | Sale | −2,450,000 | $1.60 | $3.92M | 8,900,085 |
| Todd C. Brady President and CEO, Director | Sep 7, 2023 | Option exercise | +32,953 | $0.55 | $18.12K | 1,680,322 |
| Todd C. Brady President and CEO, Director | Sep 7, 2023 | Option exercise | +48,021 | $0.55 | $26.41K | 1,728,343 |
| Todd C. Brady President and CEO, Director | Sep 7, 2023 | Tax withholding | −73,807 | $7.22 | $532.89K | 1,654,536 |
| Todd C. Brady President and CEO, Director | Sep 7, 2023 | Option exercise | +192,084 | $0.55 | $105.65K | 1,647,369 |
| Gary M. Phillips Director | Sep 7, 2023 | Option exercise | +5,437 | $0.55 | $2.99K | 14,812 |
| Neal Walker Director | Aug 22, 2023 | Option exercise | +9,604 | $0.55 | $5.28K | 15,854 |
| Ben Bronstein Director | Jun 27, 2023 | Option exercise | +9,604 | $0.55 | $5.28K | 28,248 |
| Nancy Miller-Rich Director | Apr 12, 2023 | Buy | +509 | $10.13 | $5.16K | 922 |
| Todd C. Brady President and CEO, Director | Feb 28, 2023 | Award | +238,750 | – | – | 1,455,285 |
| Advisors Llc Perceptive 10% owner | Aug 10, 2022 | Buy | +15,000 | $7.85 | $117.75K | 11,350,085 |
| Advisors Llc Perceptive 10% owner | Aug 9, 2022 | Buy | +100,000 | $7.50 | $750.00K | 11,335,085 |
| Joseph Edelman 10% owner | Aug 8, 2022 | Buy | +97,000 | $7.24 | $702.28K | 11,235,085 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Aug 5, 2022 | Buy | +141,000 | $6.95 | $979.95K | 11,138,085 |
| Joseph Edelman 10% owner | Aug 4, 2022 | Buy | +95,100 | $6.17 | $586.77K | 10,997,085 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Aug 3, 2022 | Buy | +100,000 | $5.84 | $584.00K | 10,901,985 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Aug 2, 2022 | Buy | +412,406 | $5.59 | $2.31M | 10,801,985 |
| Advisors Llc Perceptive 10% owner | Aug 1, 2022 | Buy | +144,185 | $5.05 | $728.13K | 10,389,579 |
| Advisors Llc Perceptive 10% owner | Jul 29, 2022 | Buy | +222,123 | $5.03 | $1.12M | 10,245,394 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Jul 28, 2022 | Buy | +119,392 | $5.00 | $596.96K | 10,023,271 |
| Bruce Greenberg See Remarks | Jul 15, 2022 | Award | +126,087 | – | – | 133,900 |
| Stephen Machatha Chief Development Officer | Jul 15, 2022 | Award | +185,605 | – | – | 273,263 |
| Todd C. Brady President and CEO, Director | Jun 23, 2022 | Buy | +17,700 | $3.36 | $59.47K | 1,216,535 |
| Martin Joseph Joyce Director | Jun 23, 2022 | Buy | +4,323 | $3.48 | $15.04K | 23,967 |
| Joshua Reed Chief Financial Officer | Mar 30, 2022 | Award | +93,322 | – | – | 274,825 |
| Stephen Machatha Chief Development Officer | Mar 30, 2022 | Award | +64,395 | – | – | 87,658 |
| Todd C. Brady President and CEO, Director | Mar 30, 2022 | Award | +250,000 | – | – | 1,198,835 |
| Nancy Miller-Rich Director | May 3, 2021 | Buy | +413 | $12.81 | $5.29K | 413 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | May 3, 2021 | Buy | +1,200,000 | $12.50 | $15.00M | 9,903,879 |
| Todd C. Brady President and CEO, Director | Apr 12, 2021 | Award | +46,619 | – | – | 948,835 |
| Joseph Edelman 10% owner | Jan 19, 2021 | Buy | +1,368,421 | $9.50 | $13.00M | 8,703,879 |
| Advisors Llc Perceptive 10% owner | Jan 8, 2021 | Buy | +50,000 | $7.60 | $380.00K | 7,335,458 |
| Advisors Llc Perceptive 10% owner | Jan 8, 2021 | Buy | +152,668 | $10.21 | $1.56M | 7,285,458 |
| Advisors Llc Perceptive 10% owner | Jan 8, 2021 | Buy | +347,332 | $9.21 | $3.20M | 7,132,790 |
| Advisors Llc Perceptive 10% owner | Jan 7, 2021 | Buy | +500,000 | $8.13 | $4.07M | 6,785,458 |
| Advisors Llc Perceptive 10% owner | Jul 9, 2020 | Buy | +3,200,000 | $4.25 | $13.60M | 6,285,458 |
| Richard Douglas Director | Mar 16, 2020 | Buy | +40,000 | $2.75 | $110.00K | 125,000 |
| Joshua Reed Chief Financial Officer | Mar 2, 2020 | Award | +137,707 | – | – | 173,481 |
| David McMullin Chief Commercial Officer | Mar 2, 2020 | Award | +247,480 | – | – | 255,183 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stephen Machatha Officer | Aug 12, 2025 | 22,074 | $116.11K | Aug 12, 2025 | Restricted Stock Unit Grant |
| Bruce Greenberg Officer | Aug 12, 2024 | 10,834 | $55.25K | Aug 12, 2024 | Restricted Stock Unit Award |
| Stephen Machatha Officer | Aug 12, 2024 | 16,041 | $81.81K | Aug 12, 2024 | Restricted Stock Unit Award |
| G. Machatha Stephen Officer | Mar 12, 2024 | 11,537 | $36.50K | Mar 12, 2024 | Employee Stock Purchase Plan |
| Stephen Machatha Officer | Mar 11, 2024 | 18,231 | $66.00K | Mar 11, 2024 | Restricted Stock Unit Award |
| Bruce Greenberg Officer | Mar 11, 2024 | 13,201 | $47.79K | Mar 11, 2024 | Restricted Stock Unit Award |
| Todd C. Brady Officer | Mar 11, 2024 | 183,238 | $595.52K | Mar 11, 2024 | RETAIL PURCHASE |